Prolonged Infusion of Fluorinated Pyrimidines in Gastrointestinal Malignancies: A Review of Recent Clinical Trials

References

• Staley C, Hart J, Van Hagen F. Various methods of administering 5-fluorouracil. Cancer Chemother Rep 1962; 20: 107–112
   PubMedGoogle Scholar
• Seifert P, Baker L H, Reed M L. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
   PubMed Web of Science ®Google Scholar
• Lokich J J, Bothe A, Fine N. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Lokich J J. Colorectal Cancer. Cancer Chemotherapy by Infusion, 1st ed, JJ Lokich. Percept Press, Chicago 1987; 291–303
   Google Scholar
• Lokich J J, Ahlgren J D, Gullo J J. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Ardalan B, Waldman S, Sklaver L. The pyrimidine antagonists: 5-fluorouracil and floxuridine. Cancer Chemotherapy by Infusion, 2nd ed, JJ Lokich. Percept Press, Chicago 1990; 85–121
   Google Scholar
• Hansen R M. 5-Fluorouracil by protracted venous infusion: A review of recent clinical studies. Cancer Invest 1991; 9(6)637–642
   PubMed Web of Science ®Google Scholar
• Poplin E A, Kraut M, Baker L. A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. Cancer 1991; 67: 367–371
   PubMed Web of Science ®Google Scholar
• Drewinko B, Yang L-Y. Cellular basis for the inefficiency of 5FU in human colon carcinoma. Cancer Treat Rep 1987; 71: 261–265
   PubMedGoogle Scholar
• Poon M A, O'Connell M I, Wieand H S. Biochemical modulation of fluorouracil with Ieucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9(11)1967–1972
   PubMed Web of Science ®Google Scholar
• Leichman C G, Leichman L, Spears C P. Biochemical modification of protracted infusion 5-fluorouracil with weekly leucovorin: A dose-seeking clinical trial for patients with disseininated gastrointestinal cancers. Cancer Chemother Pharmacol 1990; 26(1)57–61
   PubMed Web of Science ®Google Scholar
• Leichman C G, Leichman L, Spears C P. Phase II study of prolonged infusion 5-fluorouracil (PIFU) with weekly leucovorin (LV) in disseminated colorectal cancer (CRC). Proc Am Soc Clin Oncol 1991; 10: 437
   Google Scholar
• Teiripero M, Berg M, Block M. A phase II trial of protracted therapy with 5-fluorouracil and leucovorin in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992; 11: 571
   Google Scholar
• Veenhof C HN, Poorter P JM, Bakker D MJ. Fourteen days continuous 5-fluorouracil (5-FU) infusion and low dose oral calcium leucovorin (LV) in patients with gastrointestinal cancer. Proc Am Soc Clin Oncol 1992; 11: 539
   Google Scholar
• Hansen R, Beatty P, Quebbeman E. Continuous 5-fluorouracil (5-FU) infusion and oral calcium leucovorin (CLV). A phase I trial. Proc Am Soc Clin Oncol 1991; 10: 493
   Google Scholar
• Izzo J, Zarba J, Ph Rougier. Low dose continuous infusion (FUCI) in advanced colorectal cancer: Clinical evidence for reversal of acquiredirntrinsic resistance to 5 FU or 5FU folinic WuFo)). Proc Am Assoc Cancer Res 1992; 33: 1298
   Google Scholar
• Phax II/III study of fluorouracil (5-FU) and its modulation in advanced colorectal cancer. Southwest Oncol Group study, 8905
   Google Scholar
• Wadler S, Schwart L E, Goldman M. Fluorouracil and recombinant alfa-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7(12)1769–1775
   PubMed Web of Science ®Google Scholar
• Sparano J A, Wadler S, Einzig A. Phase I trial of prolonged continuous infusion (PCI) 5-fluorouracil (FU) and alpha-2a in-terferon (IFN): Greater FU dose intensity and responses in refractory cancer. Proc Am Soc Clin Oncol 1991; 10: 508
   Google Scholar
• John W J, Neefe J, Smith M. 5-Fluorouracil (5-FU) and interferon-α (IFN) in advanced colon cancer: The University of Kentucky experience. Proc Am Soc Clin Oncol 1992; 11: 570
   Google Scholar
• Pavlick A C, Del Gaudio N, Harper R. Salvage therapy with continuous infusion 5-fluorouracil and alpha interferon in patients with colorectal cancer. Proc Am Soc Clin Oncol 1991; 11: 565
   Google Scholar
• Kemeny N, Israel K, Niedzwiecki D. Randomized trial of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990; 8(2)313–318
   PubMed Web of Science ®Google Scholar
• Lokich J J, Cantrell J, Ahlgren J. A phase III trial of protracted inlusional SFU (PIF) vs PIF plus weekly bolus cisplatin (CDDP) in advanced measurable colon cancer (MAOP protocol 5286) Proc. Am Soc Clin Oncol 1989; 8: 104
   Google Scholar
• Hansen K, Ryan L, Anderson T. A phase III trial of bolus 5FU versus protracted infusion 5FU 2 cisplatin in metastasric colorectal cancer. An Eastern Cooperative Oncology Group study (EST 2286). Proc Am Soc Clin Oncol 1992; 11: 499
   Google Scholar
• Haisen R, Scheuri M, Vukelich M. A phase II study of 5-flutirtruracil (5FU) infusion. interferon alpha. and dipyridamole in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 481
   Google Scholar
• Isacoff W H, Jacobs A D, Taylor O. Continuous infusion (Cl) 5-fluorouracil (5-FU) combined with calcium leucovorin (LV), mitomycin-C (Mito-C), and dipyridamole (D) in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1991; 10: 483
   Google Scholar
• Lokich J J, Sonneborn H, Paul S. Phase I study of continuous venous infusion of floxuridine (5FUdR) chemotherapy. Cancer Treat Rep 1983; 67: 791–793
   PubMedGoogle Scholar
• Anderson N, Lokich J, Bern M. A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14 day infusion. Cancer 1989; 63: 233–237
   PubMed Web of Science ®Google Scholar
• Ensminger W, Niederhuber J, Gyves J. Effective control of liver metastases from colon cancer with an implanted system for hepatic arterial chemotherapy. Proc Am Soc Clin Oncol 1982; 1: 94
   Google Scholar
• Kemeny N, Daly J, Oderman P. Hepatic artery pump infusion toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 1: 595–600
   Google Scholar
• Kemeny N, Daly J M, Reichman B. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459–465
   PubMed Web of Science ®Google Scholar
• Chang A E, Schneider P D, Sugarbaker P. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 6: 685–693
   Google Scholar
• Hohn D C, Stagg R J, Friedman M A. A randomized trial of continuous intravenous hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to liver: The Northern California Oncology Group trial. J Clin Oncol 1989; 7(11)1646–1654
   PubMed Web of Science ®Google Scholar
• Rougier P, Laplanche A, Huguier M. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112–1118
   PubMed Web of Science ®Google Scholar
• Kemeny N, Seiter K, Niedzwiecki D. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer, 69(2)327
   PubMed Web of Science ®Google Scholar
• Kemeny N, Cohen A, Bertino J. Continuous infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer 1990; 65(11)2446–2450
   PubMed Web of Science ®Google Scholar
• Hohn D C, Roh M, Chase J. Prohibitive toxicity with hepatic arterial infusion (HAI) of low dose floxuridine (FUDR) and folonic acid (FA) for colorectal liver metastases. Proc Am Soc Clin Oncol 1991; 10: 459
   Google Scholar
• Selter K, Kemeny N, Cohen A. A randomized trial of hepatic arterial FUDR (F) + mitomycin + BCNU (FMB) versus FUDR alone in previously treated patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 425
   Google Scholar
• Stagg R J, Venook A P, Chase J L. Alternating hepatic intraarterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83(6)423–428
   PubMed Web of Science ®Google Scholar
• Ajlouni M I, Merrick H W, Skeel R T. Concomitant radiation and constant infusion FUdR for unresectable hepatic metastases. Am J Clin Oncol 1990; 13(6)532–535
   PubMed Web of Science ®Google Scholar
• Safi F. Continuous simultaneous intraarterial (IA) and intravenous (IV) therapy of liver metastases of colorectal carcinoma. Results of a prospective randomized trial. Proc Am Soc Clin Oncol 1992; 11: 490
   Google Scholar
• Kemeny N, Conti J, Seiter K. A phase I trial of intrahepatic fluorodeoxyuridine (FUDR) and systemic 5-fluorouracil (FU) + leucovorin (LV) in metastatic colorectal cancer: A useful adjuvant program after resection of colorectal hepatic metastases. Proc Am Soc Clin Oncol 1992; 11: 590
   Google Scholar
• Wagman L D, Kemeny M M, Leong L. A prospective randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8(11)1885–1893
   PubMed Web of Science ®Google Scholar
• Southern R B, Levi F, Haus E. Control of a murine plasmacytoma with doxorubicin-cisplatin: Dependence on circadian stage of treatment. J Natl Cancer lnst 1989; 81: 135–145
   PubMed Web of Science ®Google Scholar
• Hrushesky W JM. Circadian timing of cancer chemotherapy. Science 1985; 228: 73–75
   PubMed Web of Science ®Google Scholar
• Benavides M, Levi F, Touitou Y. Circadian rhythms in cancer patients: The need to take them into account for chemotherapy trials. Proc Am Assoc Cancer Res 1992; 33: 1335
   Google Scholar
• Hrushesky W JM, Von Roemeling R, Lanning R M. Circadian-shaped infusions of floxuridine for progressive meta-static renal cell carcinoma. J Clin Oncol 1990; 8: 1504–1513
   PubMed Web of Science ®Google Scholar
• Von Roemeling R V, Hrushesky W JM. Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer. J Clin Oncol 1989; 7: 1710–1719
   PubMed Web of Science ®Google Scholar
• Wesen C, Hrushesky W JM, Roemeling R V. Circadian modification of intra-arterial 5-fluoro-2′-deoxyuridine infusion rate reduces its toxicity and permits higher dose intensity. J Infus Chemother 1992; 2(20)69–75
   Google Scholar
• Petit E, Milano G, Levi F. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a 5-day continuous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676–1679
   PubMed Web of Science ®Google Scholar
• Focan C, Levi F, Le Couturier S. Chronotherapy of hepatic metastases from colorectal cancer by local and general infusion. Proc Am Soc Clin Oncol 1992; 11: 542
   Google Scholar
• Bjarnason G A, Kerr I, Doyle N. Phase I study of 5-fluorouracil (5-FU) and leucovorin (LV) by 14 day continuous infusion chronotherapy in patients with metastatic adenocarcinoma. Eur J Cancer 1991; 27: A528, Suppl 2
   PubMedGoogle Scholar
• Nigro N D, Vaitkevicius V K, Considine B. Combined therapy for cancer of the anal canal. A preliminary report. Dis Colon Rectum 1974; 17: 354–356
   PubMed Web of Science ®Google Scholar
• Rotman M, Aziz H. Concomitant continuous infusion chemotherapy and radiation. Cancer 1990; 65: 823–835
   PubMed Web of Science ®Google Scholar
• Franklin R, Steiger Z, Vaishampayan G. Combined modality therapy for esophageal squamous cell carcinoma. Cancer 1983; 51: 1062–1071
   PubMed Web of Science ®Google Scholar
• Leichman L, Steiger Z, Seydel H G. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: A potentially curative approach. J Clin Oncol 1984; 2: 75–79
   PubMed Web of Science ®Google Scholar
• Poplin E, Fleming T, Leichman L. Combined therapies for squamous-cell carcinoma of the esophagus. A Southwest Oncology Group study (SWOG-8037). J Clin Oncol 1987; 5: 622–628
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, Al-Sarraf M S. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593–1598
   PubMed Web of Science ®Google Scholar
• Lokich J J, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 1987; 60: 275–279
   PubMed Web of Science ®Google Scholar
• Poplin E, Kraut M, Herskovic A. Radiochemotherapy of locoregional esophageal carcinoma. Proc Am Soc Clin Oncol 1992; 11: 580
   Google Scholar